全球四特異性抗體臨床研發管線、開發技術、治療方法與市場機會展望（2026 年）

《全球四特異性抗體臨床研發管線、開發技術、治療方法和市場機會（2026）》報告的主要發現和亮點：

• 首個四重特異性抗體預計將於 2032 年獲得核准。
• 依公司、國家、適應症和階段對四特異性抗體臨床試驗進行全面分析。
• 目前有超過5種四價抗體正在進行臨床試驗。
• 目前臨床開發及未來商業化前景
• 對主要四價抗體臨床試驗的開始和完成年份的深入了解
• 公司特有技術：成熟與新興的四特異性抗體技術
• 競爭格局

四價抗體的必要性及本報告的意義

四靶點抗體代表著全球新一代生物製藥市場的新前沿，滿足了人們對高效能癌症療法日益成長的需求。儘管傳統抗體的應用已徹底改變了多種疾病的治療，但抗原逃脫、免疫刺激不足和抗藥性等挑戰依然存在，為進​​一步創新留下了空間。四靶點抗體透過同時識別四種不同的標靶結構，實現了腫瘤標靶化和免疫系統活化的雙重作用，從而彌補了這些不足。

本報告旨在對這個快速變化的市場進行全面而深入的策略觀點。報告融合了科學、臨床和商業觀點，幫助相關人員了解創新的來源及其為自身業務帶來的益處。透過將創新的早期階段與其市場影響聯繫起來，本報告協助投資者和其他市場相關人員評估哪些資產最具潛力。

報告中包含對臨床試驗的深入分析

隨著越來越多的候選藥物從臨床前階段進入臨床試驗，四價特異性抗體的臨床開發平臺日益活躍。本研究對這些進展進行了系統性的綜述，並深入分析了該領域的最新趨勢。

近期進展凸顯了目前正在研發的多種作用機制。例如，OPKO Health 的子公司 ModeX Therapeutics 正在進行一項針對 B 細胞淋巴瘤的四靶點 T 細胞銜接器「MDX2003」的 I 期臨床試驗。同時，上海復宏漢霖生物技術有限公司已獲得中國國家藥品監督管理局核准，進行針對進行性固態腫瘤患者的「HLX3901」早期臨床試驗。

本報告從多個角度對這些臨床試驗進行了檢驗，包括適應症、聯合治療、地理分佈和分層情況。透過分析這些臨床試驗的作用機制、試驗設計和標靶選擇，本報告深入探討了新型治療方法的成功可能性和發展趨勢。

引領四重特異性抗體研發的主要企業

四特異性抗體的競爭格局呈現出生技創新公司與老牌製藥公司並存的局面，雙方都在產業中扮演主導角色。每家公司都在利用其獨特的技術平台和免疫腫瘤學方面的專業知識來開發新產品。

該領域的主要企業包括ModeX Therapeutics、Molecular Partners、Innate Pharma和SystImmune。來自中國等新興地區的公司也日益嶄露頭角，四川百利藥業和北京星邁生物科技有限公司等都是活躍於該市場的公司。

開發中使用的技術平台

四特異性抗體領域的關鍵方面是利用最先進的工程平台來開發高功能性、多特異性分子。這些平台構成了創新的基礎，能夠最佳化結合親和性、穩定性和免疫反應。

QLSF Biotherapeutics 的 TECAD 平台就是一個例子。 TECAD 代表“具有親和性刺激和親和力驅動的 T 細胞銜接器”，它是一個基於雙靶點特異性和共刺激的平台。該平台旨在透過親和性驅動的結合和免疫激活，提供更有效的腫瘤治療。 QL615 是使用該平台開發的候選化合物的一個例子。

除了TECAD之外，業界還湧現出多種新技術，有助於解決與可製造性、可擴展性和安全性相關的挑戰。這將為該細分市場的發展奠定更強大的技術基礎，同時也將帶來新的差異化優勢。

四種特定抗體的未來前景

癌症生物學和免疫學領域的持續創新和進步，為四特異性抗體在未來幾年帶來了巨大的發展前景。隨著更多藥物進入研發階段，數據不斷積累，該領域預計將進入療效檢驗階段，並最終實現商業化。

此領域的進一步發展可望拓展此類抗體在固體癌治療中的應用，並整合CD28等共刺激訊號，實現更精準的標靶化。這些進步將顯著提高藥物療效，從而在未來幾年內提​​升市場價值。

四重特異性抗體市場正處於發展歷程中的關鍵轉折點，為投資者和整個產業帶來了巨大的潛力。早期創新、不斷擴充的產品線以及日益完善的市場策略，使得獲得有價值的洞察對於未來的成功變得至關重要。

目錄

第1章：調查方法

第2章：四特異性抗體簡介

• 臨床意義
• 歷史演變

第3章：四種特異性抗體的作用機制

• 多特異性抗體形式
• 免疫突觸形成和標靶結合

第4章 四特異性抗體臨床試驗概述

• 公司
• 國家
• 愛別
• 適應症

第5章：依公司、國家、適應症和階段分類的四特異性抗體臨床試驗概況

• 臨床前
• 第一階段
• 第一/二期
• 第二階段

第6章：目前臨床開發及未來商業化前景

• 目前開發狀態
• 未來商業化的潛力與機遇

第7章：四特異性抗體的治療應用（依適應症）

• 癌症
  • 固態腫瘤
  • 血液疾病
• 自體免疫疾病與發炎性疾病

第8章：四特異性抗體臨床開發趨勢分析（按地區分類）

• 中國
• 美國
• 歐洲

第9章：四特異性抗體專有技術（依公司分類）

• 已建立的平台
• 新興平台

第10章：四種特異性抗體的治療方法

• 單藥治療
• 聯合治療策略
• 精確瞄準應用

第11章 競爭格局

• Beijing StarMab Biomed Technology
• Cellemedy
• Innate Pharma
• ModeX Therapeutics (OPKO Health)
• Molecular Partners
• QLSF Biotherapeutics
• Shanghai Henlius Biotech
• Sichuan Baili Pharmaceutical
• SystImmune

Global Tetraspecific Antibodies Clinical Pipeline, Development Technologies, Therapeutic Approaches & Market Opportunity Insight 2026 Report Finding & Highlights:

• First Tetraspecific Antibodies Approval Expected By 2032
• Comprehensive Insight On Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase
• Tetraspecific Antibodies In Clinical Trials : > 5 Antibodies
• Current Clinical Development & Future Commercialization Outlook
• Key Tetraspecific Antibodies Clinical Studies Initiation & Completion Year Insight
• Tetraspecific Antibodies Established & Emerging Proprietary Technologies By Company
• Competitive Landscape

Need For Tetraspecific Antibodies & Why This Report?

Tetraspecific antibodies represent an emerging frontier in the global market for next generation biologic drugs that hold immense promise thanks to rising demand for efficacious cancer therapeutics. The use of earlier generations of antibodies has revolutionized treatments in various diseases but some shortcomings like antigen escape, inefficient immune stimulation, and drug resistance have left room for further innovation. Tetraspecific antibodies fill the gap by recognizing four different target structures at once, offering both tumor targeting and immune system stimulation at once.

This report has been developed to give an all-inclusive and strategically focused review of this fast-moving market. It integrates scientific, clinical, and business perspectives to assist stakeholders in recognizing the sources of innovations and the benefits that they have for their businesses. Through linking the early stages of innovations with their effects in the marketplace, the report helps investors and other players in this market to assess which assets hold maximum potential.

Clinical Trials Insight Included In Report

The pipeline for clinical development of tetraspecific antibodies is seeing increased activity, as more candidates move through preclinical studies into clinical testing. The study presents a well-organized review of these advancements, which can give insights into the trends within the pipeline.

Advances in recent times also underscore the range of mechanisms being developed at present. For example, ModeX Therapeutics, part of OPKO Health, is conducting Phase I studies for MDX2003, a tetraspecific T-cell engager for the treatment of B-cell lymphomas. At the same time, Shanghai Henlius Biotech has obtained approval from China's National Medical Products Administration for initial trials involving HLX3901 for patients with advanced solid tumors.

These trials are examined in a variety of perspectives, such as the indication, the combination process, geographical spread, and stratification. Through an analysis of these trials in regard to their mechanism, trial design, and selection of targets, the report is able to give an indication on the likelihood of success and the development of new therapies.

Major Companies Driving Tetraspecific Antibodies R&D

The environment that defines the tetra-specific antibodies competition involves a combination of pioneering biotech companies and legacy pharmaceutical companies, with both playing their roles in pushing the industry forward. Companies are utilizing their unique technology platforms along with their knowledge of immune oncology in developing new products.

Some of the top firms in this sector are ModeX Therapeutics, Molecular Partners, Innate Pharma, and SystImmune, among others that have emerged from developing regions like China, where companies like Sichuan Baili Pharmaceutical and Beijing StarMab Biomed Technology operate.

Technology Platforms Used For Development

An important aspect of the tetraspecific antibody landscape is the use of cutting-edge engineering platforms capable of developing highly functional multispecific molecules. Such platforms provide the basis for innovation, and it is through these platforms that binding affinities, stabilities, and immune responses can be optimized.

The TECAD platform from QLSF Biotherapeutics is one such example. TECAD stands for "T Cell Engager with Co-Stimulation, Avidity Driven" and is a platform based on dual target specificity along with co-stimulation. Through avidity-driven binding and immune activation, the platform aims to provide more effective tumor treatment. QL615 is an example of a candidate developed using this platform.

In addition to TECAD, there have been various technologies emerging in the industry which could help address challenges related to manufacturability, scalability, and safety. This will provide a stronger technological foundation for the development of this market space while offering new areas of differentiation.

Future Outlook For Tetraspecific Antibodies

There appears to be great potential for tetraspecific antibodies in the coming years due to consistent innovation and advances in knowledge about cancer biology and immunology. As more drug products advance through development and produce data, the field will be likely to move on to the next phase of validating their efficacy and progressing towards commercialization.

Further development in the field should see an increased application of this class of antibodies against solid tumors, incorporation of co-stimulatory signals such as CD28, and more precision targeting. These advancements will make the drugs much more efficacious, thus increasing the value of the market in the coming years.

The tetraspecific antibodies market offers tremendous potential at an important juncture in its evolution for investors and the industry as a whole. Given the unique confluence of early-stage innovation, growing pipeline, and increasing strategy in the market, gaining valuable insights is becoming increasingly important for future success.

Table of Contents

1. Research Methodology

2. Introduction To Tetraspecific Antibodies

• 2.1 Clinical Relevance
• 2.2 Historical Evolution

3. Tetraspecific Antibodies Mechanism Of Action

• 3.1 Multispecific Antibody Formats
• 3.2 Immune Synapse Formation & Target Engagement

4. Tetraspecific Antibodies Clinical Trials Overview

• 4.1 By Company
• 4.2 By Country
• 4.3 By Phase
• 4.4 By Indication

5. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

• 5.1 Preclinical
• 5.2 Phase I
• 5.3 Phase I/II
• 5.4 Phase II

6. Current Clinical Development & Future Commercialization Outlook

• 6.1 Current Development Landscape
• 6.2 Future Commercialization Potential & Opportunities

7. Tetraspecific Antibodies Therapeutic Application By Indication

• 7.1 Cancer
  • 7.1.1 Solid Tumors
  • 7.1.2 Hematological Disorders
• 7.2 Autoimmune & Inflammatory Diseases

8. Tetraspecific Antibody Clinical Development Trend Analysis By Region

• 8.1 China
• 8.2 US
• 8.3 Europe

9. Tetraspecific Antibodies Proprietary Technologies By Company

• 9.1 Established Platforms
• 9.2 Emerging Platforms

10. Tetraspecific Antibodies Therapeutic Approaches

• 10.1 Monotherapy Use
• 10.2 Combination Therapy Strategies
• 10.3 Precision Targeting Applications

11. Competitive Landscape

• 11.1 Beijing StarMab Biomed Technology
• 11.2 Cellemedy
• 11.3 Innate Pharma
• 11.4 ModeX Therapeutics (OPKO Health)
• 11.5 Molecular Partners
• 11.6 QLSF Biotherapeutics
• 11.7 Shanghai Henlius Biotech
• 11.8 Sichuan Baili Pharmaceutical
• 11.9 SystImmune

List of Figures

• Figure 2-1: FL518 - Structure
• Figure 2-2: CRTB6 - Structure
• Figure 2-3: LegoBody Tetraspecific Antibody Structure
• Figure 2-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage
• Figure 3-1: Tetraspecific Antibody Structure
• Figure 3-2: Tetraspecific Antibody Bringing T Cells & NK Cells In Close Proximity
• Figure 4-1: Global - Number Of Tetraspecific Antibodies Clinical Trials By Company, 2026
• Figure 4-2: Global - Number Of Tetraspecific Antibodies Clinical Trials By Company, 2026
• Figure 4-3: Global - Number Of Tetraspecific Antibodies Clinical Trials By Phase, 2026
• Figure 4-4: Global - Number Of Tetraspecific Antibodies Clinical Trials By Indication, 2026
• Figure 6-1: Global Tetraspecific Antibody Market - Future Opportunities
• Figure 7-1: GNC-039-101 Phase I Study (NCT04794972) - Initiation & Completion Year
• Figure 7-2: GNC-035-103 Phase I Study (NCT05160545) - Initiation & Completion Year
• Figure 7-3: MDX-2001-101 Phase I/II Study (NCT06239194) - Initiation & Completion Year
• Figure 7-4: GNC-038-105 Phase I/II (NCT05627856) Study - Initiation & Completion Year
• Figure 7-5: GNC-038 Phase I/II Study (NCT05485753) - Initiation & Completion Years
• Figure 7-6: GNC-035-104 Phase I/II (NCT06066203) Study - Initiation & Completion Years
• Figure 7-7: GNC-035-105 Phase I/II (NCT05944978) Study - Initiation & Completion Years
• Figure 7-8: GNC-035-101 Phase I/II (NCT05104775) Study - Initiation & Completion Years
• Figure 7-9: MP0533-CP101 Phase I/II (NCT05673057) Study - Initiation & Completion Year
• Figure 7-10: GNC-038-106 Phase I (NCT06857214) Study - Initiation & Completion Year
• Figure 7-11: GNC-039 Phase I Study (NCT04794972) - Initiation & Completion Year
• Figure 8-1: Sichuan Biokin Pharmaceutical - Clinical Pipeline
• Figure 8-2: ModeX Therapeutics - Pipeline
• Figure 8-3: Mechanism of Action - IPH6501 vs. MP0533
• Figure 9-1: DARPin Platform - Molecular Partners
• Figure 9-2: ANKET(R) Platform - Innate Pharma
• Figure 9-3: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
• Figure 9-4: STEALTH - ModeX Therapeutics
• Figure 9-5: MSTAR - ModeX Therapeutics
• Figure 9-6: MSTAR - Salient Features
• Figure 9-7: TECAD - QLSF Biotherapeutics
• Figure 9-8: Multispecific VHH Antibody Drug Platform - Beijing StarMab Biomed Technology
• Figure 9-9: MATCH - Numab
• Figure 9-10: BiXAb - Features
• Figure 9-11: Zybody - Zyngenia
• Figure 9-12: T-sphaera - Cutting-Edge Plug-and-Play Platform for Drug Development
• Figure 10-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3
• Figure 10-2: Tetraspecific Antibody Engaging CD3 T cells
• Figure 10-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB
• Figure 10-4: IPH6501 - Tetraspecific NK Cell Engager
• Figure 10-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1
• Figure 10-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody
• Figure 10-7: Novel Tetraspecific Format Developed By The Roche Pharma Research & Early Development

List of Tables

• Table 7-1: Hematological Cancers - Ongoing Clinical Trials For GNC-038
• Table 8-1: China - Ongoing Tetraspecific Antibody Clinical Trials
• Table 10-1: Monotherapy Clinical Trials For Tetraspecific Antibodies